About this article Cite this article Gu, Ym., Yuan, Qn., Li, X
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Disclaimer This content is for educational and informational purposes only and is not medical advice
Provided in lyophilized form, it is designed solely for experimental use and is not intended for human application